Advances in the targeted therapy of liposarcoma

Zhonghai Guan¹
Xiongfei Yu¹
Haahao Wang¹
Haiyong Wang¹
Jing Zhang¹
Guangliang Li²
Jiang Cao³
Lisong Teng¹

¹Department of Surgical Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, ²Department of Medicine Oncology, Zhejiang Cancer Hospital, ³Clinical Research Center, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China

Abstract: Liposarcoma (LPS) is the most common type of soft-tissue sarcoma. Complete surgical resection is the only curative means for localized disease; however, both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. An increasing number of trials with novel targeted therapy of LPS have provided encouraging data during recent years. This review will provide an overview of the advances in our understanding of LPS and summarize the results of recent trials with novel therapies targeting different genetic and molecular aberrations for different subtypes of LPS.

Keywords: well-/dedifferentiated, myxoid/round cell, pleomorphic, soft-tissue sarcoma

Introduction
Liposarcoma (LPS) is the most common type of soft-tissue sarcoma (STS), which consists of over 50 different malignancies of mesenchymal origin.¹,² According to the revised World Health Organization classification guideline published in early 2013,³ almost 11 years after the previous edition,⁴ there are three different subtypes that are widely diverse in clinicopathological and molecular characteristics: well-/dedifferentiated (WD/DD) LPS, myxoid/round-cell (MRC) LPS, and pleomorphic LPS (PLS). Complete surgical resection is the only curative means for localized disease; however, both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease.⁵,⁶ Therefore, there is now an increasing demand for more effective systemic therapies. Targeted therapy of LPS has developed in recent years as a result of a better understanding of the molecular and genetic aberrations for each histologic subtype.⁷ WD/DD are the most common subtypes of LPS.¹ WD is typically low grade, while DD is more aggressive. WD makes surgical resection challenging, owing to its occurrence most often in the deep soft tissues and to the high chance of local recurrence, which will often lead ultimately to dedifferentiation.⁸ Extremity WD LPSs always remain well differentiated and can be controlled by surgery with radiotherapy.⁹ DD has a approximately 15%–20% risk of distant metastasis and ~30% 5-year survival rate.⁴ Treatment options other than surgery for both WD/DD are limited due to their resistance to conventional cytotoxic chemotherapy and radiotherapy.⁹ Although both tumor types exhibit the same amplification of chromosome 12q13-1 including the MDM2 gene, they have very different appearances pathologically. WD is characterized by adipocyte proliferation, while DD appears with both an adipocyte-rich WD portion and a fusiform-cell-rich DD portion.¹ WD does not metastasize, but DD LPS has the potential for distant metastasis. Nearly 25%–40% of WD patients will ultimately manifest DD histology at recurrence.⁸ This phenomenon, namely, dedifferentiation, is a histologic form of tumor progression, which was also described as an extreme form of the epithelial–mesenchymal transition.¹⁰,¹¹ It is still unclear how the process of dedifferentiation happens. MRC is the second most common subtype of LPS. Myxoid-cell LPSs, lacking round cell...
areas, are considered to be less aggressive tumors, with ~90% 5-year overall survival rate compared with 50% in round-cell LPS.\textsuperscript{13} Round-cell LPS is defined as a type of myxoid-cell LPS that has an associated round-cell component in >5% of a given tumor. Round-cell transformation is represented to more aggressive clinical behavior.\textsuperscript{11} MRCs are known for their sensitivity to cytotoxic chemotherapy\textsuperscript{14} and radiotherapy\textsuperscript{15} in comparison with the other LPS subtypes\textsuperscript{16} in patients with advanced or metastatic disease. Most MRCs consistently show a reciprocal translocation t(12;16)(q13;p11.2), and less commonly, t(12;22)(q13;q12), leading to FUS-CHOP fusion and EWS-CHOP fusion, respectively.\textsuperscript{17,18} Both are thought to interfere with normal adipocytic differentiation through C/EBP and activate a number of tyrosine kinase receptor pathways including MET, RET, and PI3K/Akt. There are 12 different kinds of FUS-CHOP fusion transcripts detected to date, and they can be mainly classified into three categories: specifically, type I (exons 7-2), type II (exons 5-2), and type III (exons 8-2).\textsuperscript{19} The correlation between the types of fusion transcript and prognosis is not clear.\textsuperscript{15} Besides, four types of EWS-CHOP have been described, including exons 7-2 (type 1), exons 10-2 (type 2), exons 13-2 (type 3), and exons 13-3 (type 4), among which type 1 fusion might have a more favorable course.\textsuperscript{20} PLS is much more aggressive than the other LPS subtypes and is highly resistant to all current treatment modalities.\textsuperscript{21,22} It is the less frequent type with complex genomic gains and losses, which are similarly seen in poorly differentiated sarcomas.\textsuperscript{1}

**Therapeutic targets of LPS**

**Genetic amplification/overexpression 12q13-15 amplicon**

The hallmark genetic amplification of the 12q13-15 chromosomal interval in WD/DD implies an early and possibly critical event for LPS genesis.\textsuperscript{23} Therefore, genes included in this amplicon, which can be detected by molecular methods, such as Southern blotting, fluorescence, or chromogenic in situ hybridization, and by real-time quantitative polymerase chain reaction,\textsuperscript{24,25} are of major interest for their potential to serve as therapeutic targets.\textsuperscript{26}

The MDM2 gene, also known as HDM2 in humans, located at 12q15, is consistently amplified in almost 100% of WD/DD.\textsuperscript{27,28} MDM2 amplification results in an inhibited p53 activity with loss of function of this tumor suppressor.\textsuperscript{29} P53, which was identified in 1979\textsuperscript{30} as a transcription factor, binds to the promoter and increases expression of the MDM2 gene. In turn, the MDM2 protein binds to p53 and diminishes its activity through multiple mechanisms: 1) MDM2 exports p53 out of the nucleus, 2) it directly inhibits the transactivation function of p53, and 3) it promotes proteosome-mediated degradation of p53 through its E3 ubiquitin ligase activity.\textsuperscript{31,32} Interestingly, MDM2 can downregulate the levels of E2F1 and DP1 subunits by inducing degradation of the heterodimer.\textsuperscript{33} It has been reported that the exons 1 and 2 of HMG2, a gene located at 12q14.3 and known for being rearranged in ordinary lipomas, was consistently co-amplified with MDM2.\textsuperscript{26}

Similar to MDM2 and HMG2, cyclin dependent kinase-4 or CDK4 is also amplified in ~90% of cases of WD/DD, and represents another appealing therapeutic target.\textsuperscript{34} Mechanistically, CDK4 phosphorylates and functionally inactivates the retinoblastoma (Rb) protein and then inhibits cell-cycle progression from the G1 to the S phase.\textsuperscript{35} CDK4 inhibition would thus restore native cell-cycle regulation and prevent uncontrolled tumor cell proliferation. However, CDK4 is not present in ~10% of cases.\textsuperscript{26} It was reported that the absence of CDK4 amplification was not specifically counterbalanced by another genomic alteration, but may only represent a “MDM2-HMG2-helper” in WD/DD tumorigenesis. In their study, Italiano et al observed that reduced expression of RB1 was very frequent, independently of the CDK4 status. RB1 belongs to the RB family, codes for the pRb, which have pivotal roles in controlling fundamental cellular mechanisms such as cell cycle, differentiation, and apoptosis.\textsuperscript{36} It, therefore, appears that targeting the Rb oncoprotein deregulation in WD/DD might be a potential intervention approach.\textsuperscript{3}

YEATS4, a transcription factor involved in p53 regulation,\textsuperscript{37,38} is frequently co-amplified with MDM2 and HMG2.\textsuperscript{19} Using large-scale genomic analysis of multiple STS types, Barretina et al identified YEATS4 as a potential target in WD/DD.\textsuperscript{19} Short hairpin RNA (shRNA)-based knockdown of YEATS4 in LPS cell lines resulted in better antiproliferative effects compared with MDM2. There is accumulating evidence to support a role of YEATS4 in cancer,\textsuperscript{39} such as osteosarcoma,\textsuperscript{38} non-small-cell lung cancer,\textsuperscript{40} etc. Therefore, YEATS4 may be a suitable target for LPS therapeutic intervention. The 12q13-15 amplicon includes additional genes whose protein products may be potential targets in the future, including DDIT3 (C/EBP-zeta), TSPAN31 (SAS), CPM, DYRK2, and others.\textsuperscript{26}

**Genetically amplified targets outside the 12q13-15 amplicon**

In addition to the 12q13-15 amplicon, amplifications of 6q23 or 1p32, which are never seen in WD, have been detected in DD.\textsuperscript{42} The 6q23 amplicon includes ASK1, a gene involved in the JNK signaling pathway.\textsuperscript{43} Overexpression of ASK1
activates JNK, leading to the activation of some proteins, including JUN, and inactivation of other proteins, particularly peroxisome proliferator-activated receptor gamma (PPAR-γ), which has been demonstrated to play a key role in adipocytic differentiation. Amplification of 1p32 including the C-JUN oncogene is considered to inhibit PPAR-γ via C/EBP-β. LPS growth was inhibited by downregulating C-JUN via deoxyribozyme (DNAzyme), a drug capable of specific cleavage of target mRNA, in part by the induction of apoptosis via caspase-10 rather than through the Fas pathway. Therefore, amplifications of ASK1 and JUN may explain the inhibition of adipocytic differentiation in DD, and also may be potential therapeutic targets.

**ZIC1**, one of five ZIC family genes located at chromosome 3q24, participates in a variety of developmental processes, including neurogenesis and myogenesis. Recently, ZIC1 has been reported to be involved in the progression of human tumors including endometrial cancers, medulloblastoma, mesenchymal neoplasms, and LPS cancers. Drugs directed against ZIC1 may likewise have therapeutic benefit.

**RTKs**
Recent work has shown that WD/DD overexpress RTKs (receptor tyrosine kinases), including MET, AXL, IGFR, and EGFR, all of which may serve as targets of already available small-molecule inhibitors. Currently, there are several clinical trials with tyrosine kinase inhibitors (TKIs) as a treatment for STS patients. In addition, overexpression of RTKs including RET, IGFR1, and IGFR2 has also been demonstrated in MRC.

**Chromosome translocation**

**FUS-DDIT3/EWSR1-DDIT3 fusion protein**
The translocation of t(12;16)(q13;p11) FUS-DDIT3 fusion (also known as FUS-CHOP) in ~95% of cases and the alternative t(12;22)(q13;q12) EWSR1-DDIT3 fusion (also known as EWSR1-CHOP) present in <5% of cases are to date specific for MRC.

**FUS** is an RNA-binding protein and is expressed constitutively. The N-terminal part of FUS contains an autonomous transcriptional activation domain required for the oncogenic potential of the FUS-DDIT3 chimeric protein. On the other hand, DDIT3 is a transcription factor belonging to the (C/EBP) family, and has a central role in endoplasmic reticulum (ER) stress and DNA damage response by inducing cell cycle arrest and apoptosis. The FUS-DDIT3 fusion has distinct functions in comparison to wild-type DDIT3 and does not induce growth arrest. Therefore, the FUS-DDIT3 chimeric protein is considered to function as an abnormal transcription factor, and has been shown to induce adipocytic differentiation blockage and cell-cycle control evasion. Several FUS-DDIT3 target genes that seem to be concerned with MRC development have been identified by use of in vitro and in vivo systems. Downstream targets of FUS-DDIT3 include PPAR-γ and C/EBP-α. In addition, FUS-DDIT3 interacts with splicing factors and inhibits alternative splicing. Göransson et al have shown that IL-6 is upregulated in human fibrosarcoma cells transfected with DDIT3-GFP or FUS-DDIT3-GFP and that IL-8 was downregulated after DDIT3 transfection and upregulated after transfection with FUS-DDIT3. In addition, the DDIT3-binding C/EBP-α has been shown to interact with and inhibit the kinase activity of CDK2 and CDK4.

The Ewing sarcoma breakpoint region (EWSR1), which was initially identified in Ewing sarcoma, a malignant tumor of bone and soft tissue, has also been identified in myxoid LPS, termed EWSR1/DDIT3, with a frequency of ~5%. EWSR1-DDIT3 was also reported to have a lower incidence among the American Indian/Alaskan native and Asian/Pacific Islander populations compared with the white population. EWSR1-DDIT3 may act as an aberrant transcription factor and affect the phenotypic selection of uncommitted target cells. Suzuki et al reported that the EWSR1-DDIT3 myxoid LPS fusion protein selectively repressed the transcriptional activity of cell-lineage-specific marker genes in multipotent mesenchymal C3H10T1/2 cells.

**Deregulation of signaling pathway**

**PI3K/Akt signaling pathway**
The PI3K/Akt signaling pathway has attracted much scientific attention. PI3K mutations in the p110α catalytic subunit have been found to be very frequent in MRC tumors and associated with poor prognosis by Barretina et al in a study analyzing subtype-specific genomic alterations in 207 STS patients. These findings suggest a potential role for deregulated Akt pathway in myxoid liposarcomas (MLS) and round cell LPS (RCL) and support further investigation of PI3K/Akt inhibitors in this histological subtype. Based on the results emerging from other cancer types, PI3K-mutated tumors are highly sensitive to Akt inhibition, and PI3K sequencing could thus be a potential therapeutic target.

**C/EBP-α**

C/EBP-α belongs to a family of basic region leucine zipper transcription factors intimately involved in regulating
terminal differentiation of many cell types. It is expressed at high levels in normal tissues and cell types, but at low levels in cancer cells.\(^6\) During normal adipogenesis, \(C/EBP-\alpha\) and its partner \(PPAR-\gamma\) promote each other’s expression in a positive feedback loop to maintain high levels of the miRNAs and to maintain the differentiated state.\(^7\)

Recently, it was reported that \(C/EBP-\alpha\) and \(PPAR-\gamma\) were underepressed in DD and to a lesser extent in WD. Based on the findings that DD cell lines grown in differentiating conditions lacked the normal induction of \(C/EBP-\alpha\) expression despite partially inducing \(PPAR-\gamma\) and that \(PPAR-\gamma\) levels increased appropriately with the increase in \(C/EBP-\alpha\) in regular medium (which contains no \(PPAR-\gamma\) ligand), Wu et al\(^8\) suggested that the underexpression of \(PPAR-\gamma\) in DD is the consequence, not the cause, of \(C/EBP-\alpha\) undereexpression, and restoring \(C/EBP-\alpha\) may be a useful therapeutic approach for DD.

**Peroxisome proliferator-activated receptor gamma (PPAR\(\gamma\))**

PPARs are key regulators of normal adipocyte differentiation. \(PPAR-\gamma\), one of the isoforms, participates in the terminal adipocyte differentiation pathway. \(PPAR-\gamma\) agonist demonstrated antitumor activity in vitro in human LPS cells.\(^9,10\) Activation of \(PPAR-\gamma\) thus represents an attractive target particularly for DD, MRC, and PLS as a mechanism to revert these subtypes to a better differentiated phenotype.

**Other potential targets**

**Other genes**

Three genes, \(TOP2A\), \(PTK7\), and \(CHEK1\), were reported to be overexpressed in 140 LPS samples of all subtypes and in LPS cell lines. Once knocked down, these genes in LPS cell lines reduced proliferation and invasiveness and increased apoptosis.\(^11\) Several point mutations were reported by Barretina et al\(^12\) to be identified in CTNNB1 (\(\beta\)-catenin), CDH1 (E-cadherin), FBXW7 (a component of the ubiquitin protease ligase complex), and EPHA1 (ephrin A1), each of which has potential oncogenic effects on the LPS cell.

Another therapeutic strategy worthy of further exploration is targeting \(FUS-DDIT3\) downstream effectors. For example, CCL2, CXCL8, IL-6, vascular endothelial growth factor, the proinflammatory protein, and the matrix binder pentraxin 3 have all been found to be specifically downregulated\(^13\) by \(FUS-DDIT3\) and thus may serve as possible novel therapeutic targets.

**Micro-RNA**

Micro-RNAs (miRNAs) are considered to participate in all cellular processes of the organism,\(^14\) including the development, differentiation, metabolism, and programmed cell death, among others. miRNAs behave as tumor suppressors or oncogenes, depending on whether they target oncogenes or conventional tumor suppressors. The first evidence of miRNA deregulation in chronic lymphocytic leukemias (CLLs) was reported by Calin et al\(^84\) in 2002. Since then, the number of reports associating miRNA with cancer has been growing exponentially.\(^85\) from 0.002% of total cancer reports in 2002 to a current 2%.

Ugras et al\(^86\) reported that MiR-143 re-expression selective agents or vectors directed at miR-143 or its targets may have therapeutic value in DD, in a study profiling miRNA expression in 83 samples of WD, DD, and normal adipose tissue. They found highly abundant, downregulated miR-143 in adipose tissue. Restoring miR-143 expression in DD cells induced apoptosis, inhibited proliferation, and decreased expression of polo-like kinase 1 (PLK1).\(^87\) Therefore, treatment with a PLK1 inhibitor potently induced G2-M growth arrest and apoptosis in LPS cells. MiR-155\(^88\) was recently found to be highly expressed in WD/DD and to have a significant role in tumorigenesis and progression as an oncogenic miRNA in several cancer models.\(^89\)–\(^91\) The role for miR-155 in solid malignancy of mesenchymal origin was first reported by Zhang et al. miR-155 was the most overexpressed miRNA in the growth of DD LPS cell lines. They also identified casein kinase 1\(\alpha\) (CK1\(\alpha\)) as a direct target of miR-155 control, which enhanced \(\beta\)-catenin signaling and cyclin D1 expression, as a DD molecular driver. Borjigin et al\(^89\) identified plasminogen activator inhibitor-1 (PAI-1), a unique type of serine protease inhibitor and known to be one of the key regulators of tumor invasion and metastasis, as a novel target gene of miR-486, which has been found to be repressed in MRC tissues.

**Calreticulin**

A recent study identified several genes that were highly expressed in DD, and an overexpressed gene located in 19p13.1-13.2 chromosome was reported to encode calreticulin (CALR) that can inhibit adipocyte differentiation. Investigating the expression of CALR in 45 cases of LPSs, including 15 DD tumors, at both the protein and mRNA levels, Hisaoka et al reported that CALR was consistently expressed in the DD areas of DD LPS and commonly observed in atypical stromal cells and/or lipoblasts in the WD areas (87%), whereas large vacuolated adipocytic cells in either the tumors or normal fat were essentially negative. The downregulation of CALR by small-interfering RNA could induce adipogenesis in...
DD cells and reduce cell proliferation.93 The authors also reported that the overexpressing gene is a potential target of miR-1275.94

Cancer stem cells (CSCs)
Current knowledge considers tumors as complex heterogeneous organ-like systems with a hierarchical cellular organization. Tumor cells with stem-cell-like properties have been identified in all major human cancers.6 CSCs, described as a small population of tumor cells, possess stem-like properties, such as the ability to self-renew and differentiate into more mature cells.84 Aldehyde dehydrogenase (ALDH) and the surface molecule CD133 have recently been shown to be markers of CSCs across multiple tumor types.85 In a recent study, Stratford et al86 demonstrated that ALDH1 is expressed in 10 out of 10 LPS patient samples. Using an LPS xenograft model, they identified a small population of cells with an inducible stem cell potential, expressing both ALDH and CD133 following culturing in stem cell medium. This potential CSC population, which makes up for 0.1–1.7% of the cells, displayed increased self-renewing abilities and increased tumorigenicity, giving tumors in vivo from as few as 100 injected cells. All these findings confirmed the existence of CSCs in LPS, and provided targets for novel CSC-specific therapies. Further work, including specifically targeting and killing the CSC population in the model system, is ongoing.

Drugs and trials
Drugs for WD/DD

MDM2 inhibitors
The Nutlins, discovered by Vassilev et al at Hoffman-La Roche,99 are probably the first potent and specific MDM2 inhibitors. Nutlin-1 and Nutlin-2 are racemic compounds, and Nutlin-3a is an active enantiomer. Nutlin-3a, which has been tested in several preclinical cancer models, demonstrating positive effects,98 is a nonpeptide, small-molecule inhibitor of the MDM2–p53 interaction, thus restoring p53 activity.99 Studies evaluating the impact of Nutlin-3a on DD cells have demonstrated marked cell cycle arrest and apoptosis in vitro.61 MDM2 inhibitors activate p53 in both tumor and normal cells with wild-type p53;100 in other words, an intact p53 pathway is essential. Cells harboring mutated p53 have not been affected by Nutlin-3a. Detailed analysis of aberrations in the p53 pathways may help in predicting tumor sensitivity and resistance to p53, activating therapy by MDM2 antagonists.101 Interestingly, Nutlin-3a has recently been reported to also affect the Rb pathway by activating E2F1, and induce apoptosis in null-p53 cancer cells.102 Therefore, Nutlin-3 presents an exciting prospect for future targeted therapy. RG7112 (RO5045337) is a member of the Nutlin family and is the first MDM2 antagonist to be assessed clinically (Hoffmann-La Roche) (NCT01164033, NCT01143740, NCT00623870, and NCT00559533). Phase I trials testing RG7112 were reported at the American Society for Clinical Oncology (ASCO) 2011 meeting (Ray-Coquard et al, Proc. ASCO 2011).104 Preliminary clinical data indicate that RG7112 appears to be well tolerated in patients and shows initial evidence of clinical activity and a mechanism of action consistent with targeting of the MDM2–p53 interaction.104,105 In a preclinical assessment, the MDM2 antagonist MI-219 (spirooxindole) was reported to trigger an earlier overall biological response (12–24 hours) than Nutlin-3 (48 hours), predominantly in the form of apoptotic cell death. MI-219, but not Nutlin-3, enhanced the auto ubiquitination and degradation of MDM2. Results of the Phase I study of the MDM2 inhibitor JNJ-26854165 (NCT00676910), using continuous daily oral dosing in patients with advanced solid tumors were presented in the 2009 ASCO.106 Another MDM2 inhibitor from Hoffmann-La Roche, RO5503781, whose structure has not been disclosed, entered Phase I clinical trials at the end of 2011 (clinical trials.gov identifier: NCT01462175). A spirooxindole class of MDM2 inhibitors discovered at the University of Michigan in the US has completed IND-enabling studies by Sanofi, and Phase I clinical trials were expected to begin in 2012. Several others MDM2 inhibitors (eg, AT-219; Ascenta) are in late preclinical development.107

CDK4 inhibitors
Recent data108 suggest that the future for CDK inhibitors in cancer therapy may be in combinatory strategies. Both preclinical studies and clinical trials have demonstrated that CDK inhibitors can act in synergy with cytotoxic drugs, suggesting that CDK inhibitors work better when cells are synchronized or arrested in specific cell phases.109

Flavopiridol was the first example of a CDK4 inhibitor to be tested in clinical trials. A Phase I trial of doxorubicin and flavopiridol in STS was presented in the 2006 ASCO by D’Adamo et al110 to support that the combination of doxorubicin and flavopiridol is safe, with no unexpected toxicities. Schwartz et al reported the first in-human study of PD 0332991, an oral CDK4/6-specific inhibitor,111 enrolling patients who had either non-Hodgkin’s lymphoma or Rb-positive advanced solid tumors including WD/DD. They identified the dose-limiting toxicity (DLT) and maximum
tolerated dose (MTD) of PD 0332991 administered once daily for 21 of 28 days (3/1 schedule) in patients with Rb-positive advanced solid tumors. Recently, the authors screened 48 patients (44 of 48 had CDK4 amplification; 41 of 44 were Rb positive) in a Phase II study of PD 0332991 (NCT01209598) and demonstrated CDK4 inhibitor associated with favorable progression-free survival (PFS) in WD/DD patients with CDK4-amplification and Rb-expression whose disease had progressed despite systemic therapy.112 However, they found that no objective treatment responses were seen, suggesting not to support further exploration of flavopiridol as a mono-therapy. Co-treatment with PD 0332991 enhances multiple myeloma cell death, and is currently undergoing Phase I and II clinical trials.113,114 This kind of synergy of PD 0332991 was also shown with the anti-estrogen tamoxifen and the HER2-targeted therapy trastuzumab in ER-positive breast cancer cell lines.115

Drugs for MRC
Minor-groove DNA binders
Trabectedin is a novel chemotherapeutic drug (Ecteinascidin-743, ET743) that was isolated from Ecteinascidia turbinata, a tunicate that grows on Caribbean mangrove roots.116 It has been approved by European Medicines Agency (EMA) for the second-line therapy of STSs in 2007 and for the second-line therapy of ovarian cancer in 2009.117 Trabectedin was shown to be particularly effective in MLS by recent clinical evidence,118-120 and the high sensitivity of MLS might be related to the ability of the drug to block the transactivating ability of FUS-DDIT3 fusion protein.121 Patients treated with trabectedin could exhibit impressive clinical responses, as was evident in radiological imaging that showed decreased tumor density followed by tumor shrinkage of up to 50%.118 In a recent study evaluating the effect of prior chemotherapies on the outcomes of 129 patients with LPS and leiomyosarcoma treated with trabectedin as a 24-hour infusion every 3 weeks, Blay et al122 reported that all efficacy outcomes were better compared with patients with more extensive prior therapy. Recently, a multicenter Phase II clinical trial of neoadjuvant trabectedin in patients with localized MRC has been completed at the National Cancer Institute. Gronchi et al123 reported that 3 of 23 assessable patients had pathologi- cal complete response (pCR) [13%; 95% confidence interval (CI), 3%-34%], and that trabectedin 1.5 mg/m² given as a 24-hour iv infusion every 3 weeks is a therapeutic option in the neoadjuvant setting of MLS.

Similar to trabectedin, brostallicin (PNU-166196) is also a DNA minor-groove binder that alters the transcriptional regulation of FUS-DDIT3-induced genes.124 The antitumor activity of brostallicin has been tested in STS patients. Recently, in a Phase II study by the European Organisation for Research and treatment of Cancer (EORTC) of brostallicin in treating patients with locally advanced or metastatic STS, Leahy et al125 demonstrated that brostallicin has a manageable toxicity profile and objective tumor responses were infrequent. In addition, they suggested that the drug may warrant further investigation in view of the measured 3-month PFR of ~40% in a group of patients with a range of other STS histotypes.

Other drugs for LPS
RTK inhibitors
Drugs developed to treat diseases caused by activated RTKs are generally divided into two groups: 1) small-molecule inhibitors of the ATP-binding site of the intracellular TKD,126 and 2) anti-RTK monoclonal antibodies directing destruction of RTK-expressing cells by the immune system or by interfering with the receptor activation.127 RTKs are of established clinical benefit in various cancers, including breast, colorectal, lung, and other tumor types.128 For example, imatinib mesylate constitutes the classic example of targeted therapy in mutation-activating c-Kit gastrointestinal stromal tumors (GISTs).129 Currently, there are several ongoing clinical trials evaluating different TKIs as treatment for STS patients,55 however, seldom are specifically accruing LPS patients.

Pazopanib (GW786034), a synthetic indazolyl pyrimidine, is a novel multitargeted TKI that targets vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-kit. Pazopanib has demon- strated significant activity mainly in renal cell carcinoma (RCC) and in other malignancies.130,131 In 2009, the FDA granted its approval (Votrient®, made by GlaxoSmithKline) as a first-line monotherapy or after cytokines-based treatment in patients with advanced RCC.132 In a Phase II study enrolling 142 patients with intermediate- or high-grade advanced STS, EORTC (62043)133 reported that the PFR (12 weeks) was 18 (44%) of 41 patients in the leiomyosarcoma cohort, 18 (49%) of 37 in synovial sarcomas, 16 (39%) of 41 in other STS types, and only 5 (26%) of 19 in LPS, which actually was closed after the first stage, and thus, given insufficient activity, they doubted whether any LPS subtypes have any clinical benefit with pazopanib. In a Phase III study carried out by van der Graaf et al in 72 institutions across 13 countries, patients with angiogenesis inhibitor-naive, metastatic, STS progressing despite previous standard chemotherapy were involved. The overall survival was 12.5 months with pazopanib versus
10.7 months with placebo, which indicates that pazopanib is a new treatment option for patients with metastatic, non-adipocytic, STS after previous chemotherapy. Another Phase II study specific for advanced LPS patients is currently open (NCT01506596). A Phase II trial evaluating pazopanib activity in advanced and/or metastatic LPS (NCT01692496) after imatinib and sunitinib treatments is undergoing currently. A Phase III trial of pazopanib in patients with STS whose disease had progressed following or during prior chemotherapy was reported by EORTC (62072) and was presented in 2011 ASCO as an active drug in anthracycline-pretreated metastatic STS patients, with an increase in median PFS of 13 weeks. In 2012, the FDA and EMA approved pazopanib as second-line chemotherapy for the treatment of patients with advanced nonlipogenic STS, but still not yet for LPS, so more investigations are needed.

Irradiation when combined with TKIs has demonstrated increased efficacy in preclinical experiments. The first study of sunitinib combined with percutaneous irradiation was published by Kao et al with 59% of the patients with oligometastasis of different primary tumors receiving complete or partial remission. Similarly, the combination of radiotherapy with sorafenib might provide clinical benefits in patients with hepatocellular carcinoma (HCC), metastatic RCC, as well as gastrointestinal and other malignancies. Furthermore, the strategy of combining pazopanib with radiotherapy has also been reported recently in cervical cancer (CC) and breast cancer, all of which demonstrate potential benefits to some extent. Although the included entities cannot be compared with STSs, for which irradiation is limited due to the large tumor size and critical anatomic sites such as major vessels and nerves or vital organs, the results of the study provided an application prospect for the combination of radiotherapy and TKIs in LPS. Recently, Porzio et al reported that an LPS patient, treated with a total of 23 cycles of sunitinib at 37.5 mg daily in 4-week cycles on a compassionate use basis after receiving radiotherapy and different lines of standard chemotherapy with local progression and lung metastasis, achieved a stable disease in all sites, confirming that sunitinib may be a useful therapeutic tool in the treatment of some cases of pretreated LPS.

Nelfinavir
LPS cells were shown to express SREBP-1, the underlying mechanism for HIV protease inhibitor (PI) lipodystrophy. SREBP-1 is a member of the basic helix–loop–helix leucine zipper transcription factor family and promotes lipogenic gene expression, including PPAR-γ, so SREBP-1 and PPAR-γ cooperatively promote adipogenesis. Nelfinavir (NFV; Vira-cept), one of HIV PIs, has shown promising anticancer activity via multiple pathways. In a recent Phase I trial conducted in 20 patients with unrespectable LPS, 17 of whom had WD/DD, 2 MRC, and 1 PLS subtypes, Pan et al reported that no dose-limiting toxicities were seen after being treated with NFV, except for 1 patient who had grade-3 pancreatitis. Four patients had stable disease and one with DD experienced a partial response for 14 months. A Phase II trial of NFV in advanced LPS was under way (NCT00233948), and the results have yet to be reported.

PPAR-γ agonists
The PPAR-γ agonist not only induced adipocyte differentiation but demonstrated antitumor activity in vitro and in vivo. The activation of PPAR-γ results in cell-cycle arrest, induction of apoptosis, inhibition of angiogenesis, and cellular redifferentiation. However, the results of recent studies are inconclusive due to the low number of enrolled patients and lack of specificity for LPS. Tontonoz et al showed that the PPAR-γ agonist pioglitazone effectively induced terminal adipocytic differentiation of human LPS cells. Furthermore, they demonstrated that a combination of pioglitazone and an RXR-α-specific ligand, LG268, might have additive effects in inducing adipocytic differentiation. In a pilot clinical study, troglitazone was administered to 3 patients (two with MRC and one with PLS); histologic analysis revealed remarkable differentiation as well as inhibition of proliferation. However, in a trial involving 9 LPS patients treated with another PPAR-γ agonist rosiglitazone, clinical responses were not observed.

Very recently, Pishvaian et al reported that 5 out 31 patients (16%) enrolled in an efatutazone (CS-7017) trial with LPS and 1 patient with MRC had a durable partial response for 690 days while on therapy. Efatutazone is a novel third-generation PPAR-γ agonist that has demonstrated potent anticancer effects in preclinical models. To date, it has not been clarified whether other PPAR-γ agonists, such as balaglitazone and sulfonyl hydrazone, have therapeutic efficacy for LPSs.

PI3K/Akt/mTOR inhibitor
In a recent study evaluating the effects of NVP-BEZ235 in a panel of rhabdomyosarcoma, osteosarcoma, and Ewing’s sarcoma cell lines (LPS was not included), Manara et al reported that NVP-BEZ235 effectively blocked the pathway and also showed promising efficacy with doxorubicin and vincristine. The drug is currently undergoing Phase I/II clinical trials in advanced
cancer patients. In a mouse xenograft model of DD LPS, Smith et al reported that another PI3K/Akt/mTOR inhibitor, rapamycin, had antiproliferative effects and induced terminal differentiation.¹⁵⁷

**Sorafenib**

Sorafenib is a multitargeted TKI of raf, VEGFR1-3, PDGFRB, c-kit, and fli-3, some of which may be of relevance in STSs.¹³⁰,¹³¹ Sunitinib malate has been shown to be safe and effective both in patients with metastatic RCC or imatinib-resistant GIST, with FDA approval for both indications.²⁻⁵ Several trials of these two drugs have been carried out, which were found effective to some degree on LPS patients, but larger samples and LPS-oriented trials are needed.

**Eribulin mesylate**

Recently, eribulin mesylate was also reported to have selective activity in LPS.¹⁵⁸ Eribulin is a nontaxane inhibitor of microtubule dynamics and is currently in Phase III evaluation in LPS and leiomyosarcoma. In an open-label Phase II trial, 128 patients with progressive high-grade STS were divided into four strata: LPS (n=37), leiomyosarcoma (n=40), synovial sarcoma (n=19), and other STSs (n=32). Finally, 46.9% of LPS patients were progression-free at 12 weeks.

**Conclusion**

LPS is the second common type of STS, which is a diverse family of more than 50 distinct malignancies constituting ~1% of solid cancers.¹⁵⁹ Due to its low prevalence and diversity of each subtype’s molecular features, there are tremendous difficulties in the development of novel targeted therapies for LPS. Both preclinical and clinical trials converge on the malignancies of greater prevalence, such as gastric cancer, colon cancer, etc, but trials for LPS are really few. Another difficulty lies in the lack of complete samples of each subtype or adequate sample size in one particular research site. In addition, some molecular mechanisms still remain unknown; for example, there is almost no effective targeted therapy for PLS.

To solve these problems, first, the collaboration of different research centers will be needed to deal with both the lack of complete samples of each subtype and lack of adequate sample size, as well as for future larger scale trials. In addition, utilization of the great wealth of data that have been placed in public repositories will help overcome this problem; for example, meta-analysis based on the trials of LPSs are feasible.

Second, according to the characteristics of the development over the recent years, a better understanding of the genetic and molecular aberrations for each histologic subtype will definitely foster the development of novel therapies; thus more basic research on the molecular mechanisms are desperately needed.

Third, because of some common mechanisms in human cells, drugs that have efficacy to treat a certain disease may also be effective in the treatment of some others. For example, the PPAR-γ agonist thiazolidinedione was first used as an antidiabetic drug and later on was also reported to be effective for LPS.⁶ Similarly, some other mechanisms such as C/EBP-α, CSCs, and miRNA may provide novel research approaches.

Furthermore, as mentioned above, combination approaches, such as those of radiotherapy and TKIs and of CDK inhibitors and cytotoxic drugs, may be an attractive potential therapy.

In conclusion, in the past years, a better understanding of molecular mechanisms of distinct LPS subtypes has led to the development of targeted therapy. However, we are still in the early stages of translating these findings into clinical application. More research work is needed.

**Acknowledgment**

The authors wish to thank Prof Qinyuan Lou for critically reading the manuscript.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


136. Van Der Graaf WT, Blay J, Chawla SP, et al. PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy – an EORTC STBSG Global Network Study (EORTC 62072). *J Clin Oncol*. 2011;29(suppl).


